2A. Figure Efficacy Outcomes Stratified by Potency of Background Statin HR (95°/o Cl) Primary Composite Endpoint • Pinteraction 0.85 (0.79-0.92) All Patients 0.86 (0.75-0.98) I On maximum intensity statin 0 I 0.88 0.85 (0.78-0.93) I On less intense statin 1.0 2.5 0.4 Secondary Composite Endpoint I I 0.80 (0.73-0.88) I All Patients I I 0.78 (0.66-0.92) I -fr On maximum intensity statin I 0.81 (0.72-0.90) 0.71 I On less intense statin 1D 2.5 OA Evolocumab better Placebo better
Figure 2A. Efficacy Outcomes Stratified by Potency of Background Statin Primary Composite Endpoint All Patients On maximum intensity statin On less intense statin 0.4 Secondary Composite Endpoint All Patients On maximum intensity statin On less intense statin • I 0 I I 1.0 I I I I I I -fr I I HR (95°/o Cl) 0.85 (0.79-0.92) 0.86 (0.75-0.98) 0.85 (0.78-0.93) 2.5 0.80 (0.73-0.88) 0.78 (0.66-0.92) 0.81 (0.72-0.90) Pinteraction 0.88 0.71 OA 1D 2.5 Evolocumab better Placebo better
clinical%20efficacy%20-%20FOURIER%20trial%2c%20Giugliano%20RP%20et%20al%2c%20Lancet%202017.docx